PMID- 26262451 OWN - NLM STAT- MEDLINE DCOM- 20160506 LR - 20161125 IS - 1538-7151 (Electronic) IS - 0277-1691 (Linking) VI - 34 IP - 5 DP - 2015 Sep TI - The Significance of Mismatch Repair Deficiency in Young Patients With Endometrial Cancer. PG - 403-10 LID - 10.1097/PGP.0000000000000174 [doi] AB - The objective of this study was to identify the tumor characteristics associated with mismatch repair deficiency in young patients with endometrial carcinoma. Young patients (45 yr old or younger) with endometrial carcinoma treated by hysterectomy in our institution between July 2001 and June 2009 were identified. The clinical and pathologic data were obtained by review of clinical records. Among the 122 cases identified, paraffin sections were available in 67 cases for immunohistochemical staining and frozen tissue available in 62 cases for microsatellite instability (MSI) analysis. Both paraffin sections and frozen tissue were available in 36 cases. Among the 67 cases with immunohistochemical staining, 22 (32.8%) showed loss of expression of at least 1 mismatch repair protein. Defective MLH1 or MSH2 expression was associated with poor prognostic factors, including a higher incidence of pelvic lymph nodes metastasis (P=0.018) and higher stage (P=0.022) for MLH1, and an increased risk of lymphovascular permeation (P=0.015) for MSH2. On the contrary, defective MSH6 protein expression was associated with a lower incidence of high-grade tumors (P=0.04). Among the 62 cases with MSI analysis, 12 (19.4%) tumors were classified as microsatellite-high (MSI-H), whereas 2 (3.2%) were classified as microsatellite-low (MSI-L). There was no difference in the pathologic characteristics between MSI-stable and MSI-H tumor. We concluded that defective mismatch repair expression is important in young patients with endometrial carcinoma, with MSH6 protein being most commonly affected. The phenotype resulting from defective MSH6 expression was different from that caused by MLH1 or MSH2 loss. FAU - Chu, Mandy Man-Yee AU - Chu MM AD - Departments of Obstetrics and Gynecology (M.M.-Y.C., S.S.L., K.-F.T., H.Y.-S.N.) Pathology (P.P.-C.I., A.N.-Y.C.), The University of Hong Kong, Queen Mary Hospital, Hong Kong. FAU - Liu, Stephanie Si AU - Liu SS FAU - Tam, Kar-Fai AU - Tam KF FAU - Ip, Philip Pun-Ching AU - Ip PP FAU - Cheung, Annie Nga-Yin AU - Cheung AN FAU - Ngan, Hextan Yuen-Sheung AU - Ngan HY LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Int J Gynecol Pathol JT - International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists JID - 8214845 RN - 0 (Adaptor Proteins, Signal Transducing) RN - 0 (DNA-Binding Proteins) RN - 0 (G-T mismatch-binding protein) RN - 0 (MLH1 protein, human) RN - 0 (Nuclear Proteins) RN - EC 3.6.1.3 (MSH2 protein, human) RN - EC 3.6.1.3 (MutL Protein Homolog 1) RN - EC 3.6.1.3 (MutS Homolog 2 Protein) RN - Turcot syndrome SB - IM MH - Adaptor Proteins, Signal Transducing/analysis/genetics MH - Adult MH - Brain Neoplasms/*genetics/pathology MH - Colorectal Neoplasms/*genetics/pathology MH - DNA-Binding Proteins/analysis/genetics MH - Endometrial Neoplasms/*genetics/pathology/surgery MH - Female MH - Gene Expression MH - Humans MH - Hysterectomy MH - Immunohistochemistry MH - Lymphatic Metastasis MH - Microsatellite Instability MH - Middle Aged MH - MutL Protein Homolog 1 MH - MutS Homolog 2 Protein/analysis/genetics MH - Neoplasm Staging MH - Neoplastic Syndromes, Hereditary/*genetics/pathology MH - Nuclear Proteins/analysis/genetics MH - Pelvis MH - Prognosis EDAT- 2015/08/12 06:00 MHDA- 2016/05/07 06:00 CRDT- 2015/08/12 06:00 PHST- 2015/08/12 06:00 [entrez] PHST- 2015/08/12 06:00 [pubmed] PHST- 2016/05/07 06:00 [medline] AID - 00004347-201509000-00001 [pii] AID - 10.1097/PGP.0000000000000174 [doi] PST - ppublish SO - Int J Gynecol Pathol. 2015 Sep;34(5):403-10. doi: 10.1097/PGP.0000000000000174.